Business Context and Reporting Period
This Form 8-K is a current report filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on April 9, 2021. The filing addresses a corporate administrative event regarding the company's transfer agent.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 8.01 (Other Events) and contains no financial statements or performance data.
Material Changes
The material change reported is the appointment of American Stock Transfer & Trust Company, LLC ("AST") as the company's new transfer agent and registrar, effective April 9, 2021. All registered shares of common stock were transferred from the previous agent, Olde Monmouth Stock Transfer Co., to AST.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document focuses solely on the administrative change of the transfer agent.
Investor Verification Checklist
- Verify the new transfer agent contact details: American Stock Transfer & Trust Company, LLC, 6201 15th Avenue, Brooklyn, NY 11219, (800) 937-5449.
- Confirm that all registered shares have been successfully transferred from Olde Monmouth Stock Transfer Co. to AST.
- Note that the company trades on the Nasdaq Capital Market under the symbol OCUP.
- Review subsequent filings for financial performance data, as this 8-K contains none.